News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
429,439 Results
Type
Article (27205)
Company Profile (130)
Press Release (402104)
Multimedia
Podcasts (77)
Webinars (11)
Section
Business (130852)
Career Advice (1296)
Deals (24065)
Drug Delivery (103)
Drug Development (59272)
Employer Resources (122)
FDA (9874)
Job Trends (9962)
News (228169)
Policy (21662)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (1479)
Accelerated approval (5)
Adcomms (17)
Allergies (62)
Alliances (32618)
ALS (56)
Alzheimer's disease (861)
Antibody-drug conjugate (ADC) (106)
Approvals (9892)
Artificial intelligence (175)
Autoimmune disease (19)
Automation (7)
Bankruptcy (241)
Best Places to Work (7578)
BIOSECURE Act (16)
Biosimilars (103)
Biotechnology (61)
Bladder cancer (40)
Brain cancer (19)
Breast cancer (176)
Cancer (1484)
Cardiovascular disease (138)
Career advice (1076)
Career pathing (24)
CAR-T (79)
Cell therapy (214)
Cervical cancer (10)
Clinical research (49450)
Collaboration (561)
Compensation (208)
Complete response letters (24)
COVID-19 (1592)
CRISPR (25)
C-suite (171)
Cystic fibrosis (68)
Data (1510)
Decentralized trials (2)
Denatured (18)
Depression (37)
Diabetes (182)
Diagnostics (3329)
Digital health (7)
Diversity (7)
Diversity, equity & inclusion (37)
Drug discovery (95)
Drug pricing (112)
Drug shortages (31)
Duchenne muscular dystrophy (68)
Earnings (54292)
Editorial (34)
Employer branding (17)
Employer resources (109)
Events (59082)
Executive appointments (510)
FDA (10643)
Featured Employer (24)
Friedreich's ataxia (3)
Frontotemporal dementia (3)
Funding (431)
Gene editing (57)
Generative AI (20)
Gene therapy (179)
GLP-1 (663)
Government (2726)
Grass and pollen (3)
Guidances (38)
Healthcare (10141)
Huntington's disease (15)
IgA nephropathy (22)
Immunology and inflammation (93)
Indications (24)
Infectious disease (1705)
Inflammatory bowel disease (94)
Inflation Reduction Act (8)
Influenza (37)
Intellectual property (70)
Interviews (180)
IPO (10518)
IRA (46)
Job creations (2708)
Job search strategy (956)
Kidney cancer (9)
Labor market (27)
Layoffs (321)
Leadership (16)
Legal (5066)
Liver cancer (42)
Lung cancer (233)
Lymphoma (114)
Machine learning (3)
Management (42)
Manufacturing (234)
MASH (60)
Medical device (5189)
Medtech (5192)
Mergers & acquisitions (13916)
Metabolic disorders (578)
Multiple sclerosis (59)
NASH (21)
Neurodegenerative disease (59)
Neuropsychiatric disorders (25)
Neuroscience (1229)
NextGen: Class of 2025 (3470)
Non-profit (2119)
Northern California (1460)
Now hiring (24)
Obesity (342)
Opinion (211)
Ovarian cancer (50)
Pain (76)
Pancreatic cancer (51)
Parkinson's disease (93)
Partnered (12)
Patents (174)
Patient recruitment (64)
Peanut (35)
People (37947)
Pharmaceutical (74)
Pharmacy benefit managers (21)
Phase I (15140)
Phase II (21168)
Phase III (16997)
Pipeline (930)
Policy (131)
Postmarket research (1885)
Preclinical (5490)
Press Release (38)
Prostate cancer (79)
Psychedelics (24)
Radiopharmaceuticals (177)
Rare diseases (285)
Real estate (3706)
Recruiting (41)
Regulatory (15335)
Reports (30)
Research institute (1328)
Resumes & cover letters (197)
Rett syndrome (4)
RNA editing (2)
RSV (36)
Schizophrenia (63)
Series A (70)
Series B (43)
Service/supplier (8)
Sickle cell disease (40)
Southern California (1385)
Special edition (17)
Spinal muscular atrophy (121)
Sponsored (18)
Startups (2343)
State (2)
Stomach cancer (12)
Supply chain (59)
Tariffs (37)
The Weekly (57)
United States (13673)
Vaccines (403)
Venture capitalists (32)
Weight loss (257)
Women's health (23)
Worklife (13)
Date
Today (126)
Last 7 days (354)
Last 30 days (1667)
Last 365 days (21684)
2025 (6458)
2024 (23008)
2023 (25825)
2022 (34304)
2021 (36146)
2020 (34285)
2019 (27890)
2018 (21464)
2017 (21843)
2016 (20688)
2015 (24179)
2014 (18628)
2013 (15244)
2012 (16398)
2011 (16843)
2010 (15323)
Location
Africa (546)
Alabama (41)
Alaska (4)
Arizona (85)
Arkansas (10)
Asia (29746)
Australia (4054)
California (3425)
Canada (1329)
China (381)
Colorado (154)
Connecticut (133)
Delaware (87)
Europe (62271)
Florida (561)
Georgia (105)
Idaho (20)
Illinois (303)
India (22)
Indiana (215)
Iowa (4)
Japan (134)
Kansas (68)
Kentucky (19)
Louisiana (8)
Maine (26)
Maryland (470)
Massachusetts (2728)
Michigan (101)
Minnesota (191)
Mississippi (1)
Missouri (38)
Montana (18)
Nebraska (15)
Nevada (31)
New Hampshire (19)
New Jersey (1306)
New Mexico (23)
New York (1118)
North Carolina (664)
North Dakota (2)
Northern California (1460)
Ohio (109)
Oklahoma (5)
Oregon (25)
Pennsylvania (791)
Puerto Rico (11)
Rhode Island (23)
South America (793)
South Carolina (9)
South Dakota (1)
Southern California (1385)
Tennessee (49)
Texas (478)
Utah (79)
Virginia (102)
Washington D.C. (49)
Washington State (363)
West Virginia (1)
Wisconsin (30)
429,439 Results for "amo pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
AMO Pharma Completes Meeting with U.S. FDA and Outlines Plans to Advance Clinical Development of AMO-02 (tideglusib) in Treatment of Myotonic Dystrophy
AMO Pharma Limited provided an update on plans to advance the clinical development program for AMO-02, the company’s investigational therapy in development for the treatment of Type 1 myotonic dystrophy, following a recent meeting with the U.S. Food and Drug Administration.
May 2, 2024
·
5 min read
Business
AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy
AMO Pharma Limited announced a collaboration with Population Health Research Institute, a joint institute of McMaster University and Hamilton Health Sciences in Canada, to advance a clinical proof of concept trial to assess the efficacy of AMO-02, AMO Pharma’s investigational oral glycogen synthase kinase 3 beta inhibitor, in the treatment of genotype positive arrhythmogenic cardiomyopathy.
February 15, 2024
·
4 min read
Opinion
Companies Take Multiple Tacks Against Myotonic Dystrophy Type 1
With its recent data drop for an oligonucleotide candidate, Dyne Therapeutics signals it may become a frontrunner in this disease space alongside Avidity Biosciences, Lupin and AMO Pharma.
February 17, 2025
·
4 min read
·
Jia Jie Chen
Drug Development
AMO Pharma Announces Preclinical Data Showing AMO-02 Improves Muscle Function, Glucose Handling and CNS function in Mouse Models of Duchenne Muscular Dystrophy
AMO Pharma Limited (“AMO Pharma”) today announced initial preclinical data from a study of the use of the company’s investigational therapy AMO-02 in the treatment of Duchenne muscular dystrophy (DMD).
September 19, 2023
·
5 min read
AMO Pharma Announces Affirming Data from REACH-CDM Clinical Trial for AMO-02 in Treatment of Myotonic Dystrophy
AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with limited or no treatment options, announced results from the company’s REACH-CDM clinical study of the investigational therapy AMO-02 in the treatment of children and adolescents with congenital myotonic dystrophy.
September 6, 2023
·
6 min read
Compensation
Top 6 Highest-Paid Pharma CEOs in 2024
Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.
April 16, 2025
·
7 min read
·
Annalee Armstrong
Europe
With Tariffs Looming, EU and US Pharmas Make Demands of European Commission
Playing both sides of trade war, pharma companies are asking for certain compensations for scientific innovation and a smoother regulatory framework.
April 16, 2025
·
2 min read
·
Tristan Manalac
Government
Trump Tariffs Miss Pharma For Now, But Uncertainties Loom
Pharma’s reprieve from Donald Trump’s tariffs is expected to be temporary, with Leerink analysts anticipating possible sector-specific duties “in the next month or so.”
April 3, 2025
·
2 min read
·
Tristan Manalac
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
·
2 min read
·
Tristan Manalac
Business
Five Biggest Drug Face-Offs in Pharma History
Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of rivalry that includes blockbuster drugs Keytruda, Humira and Eliquis.
April 9, 2025
·
9 min read
·
Tristan Manalac
1 of 42,944
Next